Cargando…
Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study
Rare data reported tacrolimus-induced liver injury (tac-DILI) in real world. We performed a nested case-control analysis of 1,010 renal transplant recipients. Recipients with tac-DILI were randomly matched at a ratio of 1:4 by the year of admission to the remaining recipients without tac-DILI to exp...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040645/ https://www.ncbi.nlm.nih.gov/pubmed/36992828 http://dx.doi.org/10.3389/fphar.2023.1126765 |
_version_ | 1784912522323689472 |
---|---|
author | Lv, Binbin Liu, Longshan Liu, Xiaoman Huang, Min Chen, Xiao Tang, Kejing Wang, Changxi Chen, Pan |
author_facet | Lv, Binbin Liu, Longshan Liu, Xiaoman Huang, Min Chen, Xiao Tang, Kejing Wang, Changxi Chen, Pan |
author_sort | Lv, Binbin |
collection | PubMed |
description | Rare data reported tacrolimus-induced liver injury (tac-DILI) in real world. We performed a nested case-control analysis of 1,010 renal transplant recipients. Recipients with tac-DILI were randomly matched at a ratio of 1:4 by the year of admission to the remaining recipients without tac-DILI to explore risk factors. The incidence of tac-DILI was 8.9% (95% CI = 7.2–10.7%). The most common type was cholestatic pattern (6.7%, 95% CI = 5.2–8.3%), followed by hepatocellular (1.6%, 95% CI = 0.8–2.4%) and mixed patterns (0.6%, 95% CI = 0.1–1.1%). 98.9% of recipients with tac-DILI have mild severity. The latency period were 42.0 (range, 21.5–99.8 days), 14.0 (range, 9.0–80.3 days), 16.0 (range, 11.5–24.5 days), and 49.0 days (range, 28.0–105.6 days) for total, hepatocellular, mixed, and cholestatic patterns, respectively. Baseline ALP level (OR = 1.015, 95% CI = 1.006–1.025, p = 0.002), age (OR = 0.971, 95% CI = 0.949–0.994, p = 0.006), and body weight (OR = 0.960, 95% CI = 0.940–0.982, p < 0.001) were independent risk factors. In conclusion, cholestatic pattern represents the most frequent type of tac-DILI. Young age, low body weight and abnormal baseline ALP level were risk factors. |
format | Online Article Text |
id | pubmed-10040645 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100406452023-03-28 Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study Lv, Binbin Liu, Longshan Liu, Xiaoman Huang, Min Chen, Xiao Tang, Kejing Wang, Changxi Chen, Pan Front Pharmacol Pharmacology Rare data reported tacrolimus-induced liver injury (tac-DILI) in real world. We performed a nested case-control analysis of 1,010 renal transplant recipients. Recipients with tac-DILI were randomly matched at a ratio of 1:4 by the year of admission to the remaining recipients without tac-DILI to explore risk factors. The incidence of tac-DILI was 8.9% (95% CI = 7.2–10.7%). The most common type was cholestatic pattern (6.7%, 95% CI = 5.2–8.3%), followed by hepatocellular (1.6%, 95% CI = 0.8–2.4%) and mixed patterns (0.6%, 95% CI = 0.1–1.1%). 98.9% of recipients with tac-DILI have mild severity. The latency period were 42.0 (range, 21.5–99.8 days), 14.0 (range, 9.0–80.3 days), 16.0 (range, 11.5–24.5 days), and 49.0 days (range, 28.0–105.6 days) for total, hepatocellular, mixed, and cholestatic patterns, respectively. Baseline ALP level (OR = 1.015, 95% CI = 1.006–1.025, p = 0.002), age (OR = 0.971, 95% CI = 0.949–0.994, p = 0.006), and body weight (OR = 0.960, 95% CI = 0.940–0.982, p < 0.001) were independent risk factors. In conclusion, cholestatic pattern represents the most frequent type of tac-DILI. Young age, low body weight and abnormal baseline ALP level were risk factors. Frontiers Media S.A. 2023-03-13 /pmc/articles/PMC10040645/ /pubmed/36992828 http://dx.doi.org/10.3389/fphar.2023.1126765 Text en Copyright © 2023 Lv, Liu, Liu, Huang, Chen, Tang, Wang and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Lv, Binbin Liu, Longshan Liu, Xiaoman Huang, Min Chen, Xiao Tang, Kejing Wang, Changxi Chen, Pan Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study |
title | Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study |
title_full | Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study |
title_fullStr | Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study |
title_full_unstemmed | Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study |
title_short | Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study |
title_sort | incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: a nested case-control study |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040645/ https://www.ncbi.nlm.nih.gov/pubmed/36992828 http://dx.doi.org/10.3389/fphar.2023.1126765 |
work_keys_str_mv | AT lvbinbin incidenceclinicalfeaturesandriskfactorsoftacrolimusinducedidiosyncraticliverinjuryinrenaltransplantrecipientsanestedcasecontrolstudy AT liulongshan incidenceclinicalfeaturesandriskfactorsoftacrolimusinducedidiosyncraticliverinjuryinrenaltransplantrecipientsanestedcasecontrolstudy AT liuxiaoman incidenceclinicalfeaturesandriskfactorsoftacrolimusinducedidiosyncraticliverinjuryinrenaltransplantrecipientsanestedcasecontrolstudy AT huangmin incidenceclinicalfeaturesandriskfactorsoftacrolimusinducedidiosyncraticliverinjuryinrenaltransplantrecipientsanestedcasecontrolstudy AT chenxiao incidenceclinicalfeaturesandriskfactorsoftacrolimusinducedidiosyncraticliverinjuryinrenaltransplantrecipientsanestedcasecontrolstudy AT tangkejing incidenceclinicalfeaturesandriskfactorsoftacrolimusinducedidiosyncraticliverinjuryinrenaltransplantrecipientsanestedcasecontrolstudy AT wangchangxi incidenceclinicalfeaturesandriskfactorsoftacrolimusinducedidiosyncraticliverinjuryinrenaltransplantrecipientsanestedcasecontrolstudy AT chenpan incidenceclinicalfeaturesandriskfactorsoftacrolimusinducedidiosyncraticliverinjuryinrenaltransplantrecipientsanestedcasecontrolstudy |